May 07, 2025

Therapy With a Tyrosine Kinase Inhibitor for EGFR-Variant Lung Adenocarcinoma: Lessons From Chronic Myeloid Leukemia?

Unresolved issues persist in treating EGFR-variant lung adenocarcinoma with tyrosine kinase inhibitors, contrasting with chronic myeloid leukemia (CML) therapy. Comparisons reveal complexities and uncertainties in patient selection, therapy monitoring, and treatment duration.

The ASCO Post

May 02, 2025

Dose Escalation of Fluorodeoxyglucose PET–Guided Radiotherapy for Locally Advanced NSCLC

In an analysis from the Scandinavian phase III NARLAL2 trial, reported in the Journal of Clinical Oncology, Schytte et al found that heterogeneously dose-escalated radiotherapy guided by fluorodeoxygl...

The ASCO Post

April 29, 2025

AACR 2025: Oral HER2-Targeted Therapy for Advanced HER2-Mutated Lung Cancer

The novel HER2-targeted tyrosine kinase inhibitor zongertinib elicited durable responses in patients with advanced, previously treated non–small cell lung cancer (NSCLC) that harbored a HER2 mutation,...

The ASCO Post

April 24, 2025

Several Trials Show Clinical Activity With Osimertinib in Advanced EGFR-Mutant Non–Small Cell Lung Cancer

Updates from several clinical trials of the EGFR tyrosine kinase inhibitor osimertinib across stages and settings of EGFR-mutated non–small cell lung cancer (NSCLC) were presented at the European Lun...

The ASCO Post

April 24, 2025

Final Results of LIBRETTO-001: Selpercatinib in RET Fusion–Positive NSCLC

As reported in the Journal of Clinical Oncology by Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, and colleagues, final results of the reg...

The ASCO Post

April 18, 2025

Activity of ROS1 TKI in NSCLC

A pooled analysis of the phase II TRUST-I and TRUST-II trials reported efficacy and safety findings on the use of the oral next-generation ROS1 tyrosine kinase inhibitor (TKI) taletrectinib in ROS1-po...

The ASCO Post

April 15, 2025

Early Research Evaluates Association Between Diet and Lung Cancer Risk

The long-term impact of diet on health has been well studied, leading to guidance about limiting the consumption of red meat, alcohol, and other foods associated with an increased risk of malignancies...

The ASCO Post

March 06, 2025

Can Plasma ctDNA Kinetics Predict Response to Systemic Therapy in Advanced NSCLC?

Based on a systematic review and meta-analysis, plasma circulating tumor DNA (ctDNA) kinetics was found to be predictive of survival outcomes in patients with advanced non–small cell lung cancer (NSCL...

The ASCO Post

February 17, 2023

Study Finds Neoadjuvant Nivolumab Led to Improved 5-Year Survival Outcomes in Patients With Resectable NSCLC

The results from a 5-year follow-up analysis of a small clinical trial of patients with stage I to IIIA non­–small cell lung cancer (NSCLC) who were treated with nivolumab for 4 weeks before surgery s...

The ASCO Post